CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 92 filers reported holding CONCERT PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $201,000 | -60.5% | 40,300 | 0.0% | 0.00% | – |
| Q4 2020 | $509,000 | +28.5% | 40,300 | 0.0% | 0.00% | – |
| Q3 2020 | $396,000 | -1.2% | 40,300 | 0.0% | 0.00% | – |
| Q2 2020 | $401,000 | +26.1% | 40,300 | +11.9% | 0.00% | – |
| Q1 2020 | $318,000 | -4.2% | 36,000 | 0.0% | 0.00% | – |
| Q4 2019 | $332,000 | +56.6% | 36,000 | 0.0% | 0.00% | – |
| Q3 2019 | $212,000 | -50.9% | 36,000 | 0.0% | 0.00% | – |
| Q2 2019 | $432,000 | +30.9% | 36,000 | +31.9% | 0.00% | – |
| Q1 2019 | $330,000 | +3.4% | 27,300 | +7.5% | 0.00% | – |
| Q4 2018 | $319,000 | -7.8% | 25,400 | +9.0% | 0.00% | – |
| Q3 2018 | $346,000 | -7.0% | 23,300 | +5.4% | 0.00% | – |
| Q2 2018 | $372,000 | -8.1% | 22,100 | +24.9% | 0.00% | – |
| Q1 2018 | $405,000 | +13.4% | 17,700 | +28.3% | 0.00% | – |
| Q4 2017 | $357,000 | +94.0% | 13,800 | +10.4% | 0.00% | – |
| Q3 2017 | $184,000 | +5.7% | 12,500 | 0.0% | 0.00% | – |
| Q2 2017 | $174,000 | – | 12,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 2,253,000 | $7,097,000 | 0.26% |
| INGALLS & SNYDER LLC | 1,358,573 | $4,280,000 | 0.19% |
| RA Capital Management | 3,033,603 | $9,556,000 | 0.17% |
| Kensington Investment Counsel, LLC | 85,483 | $269,000 | 0.16% |
| Perceptive Advisors | 4,301,282 | $13,548,000 | 0.10% |
| NewEdge Wealth, LLC | 381,326 | $1,201,000 | 0.05% |
| Black Diamond Financial, LLC | 46,000 | $145,000 | 0.05% |
| Birchview Capital, LP | 20,000 | $63,000 | 0.04% |
| XTX Topco Ltd | 14,305 | $45,000 | 0.02% |
| Alyeska Investment Group, L.P. | 548,090 | $1,726,000 | 0.02% |